Strategic Immuno-Monitoring of Patient Therapy (SIMPATHY) in the context of Basket of Baskets (BoB) trial – Atezolizumab Module

The crucial questions that SIMPATHY will start to address are:

  • How to identify tumours that will respond?
  • How to identify why some initially responsive tumours become resistant and how to avoid this or render them responsive again?
  • How to transform non-responsive tumours into responsive tumours?

In order to do so the SIMPATHY proposal aims to produce a detailed map of the tumour immune microenvironment before, during and after failure of ICI treatment with the anti-PD-L1 monoclonal atezolizumab, contextualized with genomic and systemic immune features. This may allow identification of novel biomarkers across cancers of different cell origin. Recent results have shown that pre-treatment analyses may not be sufficient to predict response but that early biopsies on treatment may provide more useful information.

The context of BoB for SIMPATHY allows:

  • Matched trial-grade clinical data.
  • Genomic profiling of all baseline tumour samples with the Cancer Core Europe (CCE) gene panel and whole exome sequencing.
  • PBMC, cfDNA analyses.
  • Simple integration of further translational assays for SIMPATHY within established infrastructure, with required state-of-the-art assays available across the CCE centers.
  • Experience of CCE physicians in obtaining high success rates for baseline and repeat biopsies.
  • Bioinformatics expertise shared across CCE centres for data analysis.

More information: Gary Doherty, project lead,

Are you interested in collaborating with us, or do you wish to get more involved in our activities?

Contact us, and we will get back to you:

If you are working for a CCE-centre, please contact your local CCE coordinator.

If you are a patient and interested in treatments or you want to join a trial, please contact your local hospital.